HSAs are being touted as a way to make healthcare more affordable. But it’s more complicated than that.

Several million Americans signed up for health savings accounts (HSAs) this year as medical costs and insurance premiums rise. HSAs, a decades-old tax-favored vehicle being promoted by conservative lawmakers including President Donald Trump as a fix for healthcare affordability, primarily benefit wealthier Americans and are a more complicated solution than proponents suggest.

Analysis

HSAs are shifting more out-of-pocket risk to consumers in a way that magnifies price sensitivity for low-frequency, high-ticket items (imaging, elective surgery, specialty drugs). That creates a rolling demand headwind for providers and device manufacturers over the next 6–18 months as newly enrolled HSA holders triage care — expect utilization lags rather than immediate margin relief for payors.

A second-order beneficiary is firms that administer and invest HSA balances: custodians, payroll/benefit platforms, and brokerage arms capture recurring fee and float economics as balances move from cash to invested assets. If adoption keeps growing, incremental AUM flows behave like a sticky workplace-savings channel (think slower but more durable than a promotional deposit), meaning 3–5% organic revenue upside for dominant custodians over 2–4 years under conservative take-rate assumptions.

Political risk is the dominant catalyst: legislative expansions (higher contribution caps, broader tax treatment, portability) would turbocharge flows and favor custodians/asset managers; a Democratic policy pivot or targeted regulation (e.g., caps on investable HSA funds or tighter consumer protections) would reverse the trade quickly. Watch election cadence and committee hearings over the next 6–12 months as binary catalysts; operational metrics to monitor are monthly HSA contribution run-rate, invested-balance penetration, and elective-procedure volumes at large hospital systems.

Key Decisions for Investors

• Go long HQY (HealthEquity) — buy a 9–12 month call or 12-month call spread to capture accelerated HSA flows and higher invested-balance penetration. Target +40–80% upside if invested balances grow 15–25% YoY; set a 25–30% downside limit if legislative momentum stalls or custody wins slow.
• Pair trade: long SCHW (Schwab) vs short SYK (Stryker) for 6–12 months — Schwab captures incremental custody/AUM fees as HSAs move into brokerage, while Stryker is exposed to elective-orthopedic procedure deferral. Aim for a 2:1 reward:risk where a 20% outperformance by SCHW over SYK nets ~+30% on the pair; cut if hospital volumes normalize in two consecutive months.
• Long ADP/PAYX (payroll processors) on a 3–9 month horizon — they win incremental admin-fee cross-sell and simplified payroll deductions for HSA contributions. Position size modest (5–8% of book long exposure) and hedge with a healthcare-services hedge if political risk spikes.
• Short select elective-procedure-centric names (MDT, selected specialty pharma with concentrated outpatient volumes) on a 6–12 month basis — anticipate 10–25% downside from utilization pressure. Use tight stops aligned to 10–12% of position value and monitor monthly elective procedure volumes and CMS utilization data as triggers.